Evidence map›Paper›PMID 39760839›Full record

ArticleCell biochemistry and biophysics2025

Synergistic Inhibition of Breast Carcinoma Cell Proliferation by Quercetin and Sulforaphane via Activation of the ERK/MAPK Pathway.

Ranmei Wei, Xingchen Pan, Danni Cai, Lili Pan

Abstract read
PubMed Publisher
In one paragraph

Article in Cell biochemistry and biophysics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Ranmei Wei *Department of Breast Diseases, Hospital of Traditional Chinese Medicine of Qiqihar, Qiqihar, Heilongjiang, China.
Xingchen Pan *Department of the 0perating Room,Huaian Hospital of Huaian City, Huaian Cancer Hospital, Huaian, Jiangsu, China.
Danni CaiOutpatient Department, General hospital of the western theater command of Chinese people's liberation army, Chengdu, Sichuan, China.
Lili PanPharmacy Administration Office, The Third Hospital of Nanchang City, Jiangxi Province, Nanchang, Jiangxi, China. panlili@ncmc.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the contemporary era of drug discovery, herbal treatments have demonstrated an unparalleled ability to produce anticancer drugs. An important part of the therapy of cancer is the use of plants and their by-products via analogues, which alter the tumor microenvironment and several signaling pathways. The objective of the current investigation was to conclude the rate at which the herbal medications quercetin (QT) and sulforaphane (SFN) repressed the growth of breast carcinoma cells in MDA-MB-231 by preventing the ERK/MAPK signaling systems. The cells were assessed for several studies after being subjected to different concentrations (0-70 µM) of QT and SFN (QT + SFN) for duration of 24 h. We investigated the combination that QT + SFN generated cytotoxicity using the MTT assay. The DCFH-DA staining technique was utilized to assess ROS. The protein spectra of survival of cells, cell cycle progression, and apoptosis were evaluated employing flow cytometry and western blotting. The consequences illustrated that the relative cytotoxicity of QT and SFN was roughly 28.74 μM and 39.87 μM for MDA-MB-231 cells, respectively. Following the 24-h incubation period, MDA-MB-231 cells exhibit considerable cytotoxicity when QT and SFN are combined, with IC

Indexed as

Breast NeoplasmsIsothiocyanatesMAP Kinase Signaling SystemQuercetinApoptosisCell Line, TumorCell ProliferationDrug SynergismExtracellular Signal-Regulated MAP KinasesFemaleHumansReactive Oxygen SpeciesSulfoxidesExtracellular Signal-Regulated MAP KinasesIsothiocyanatesQuercetinReactive Oxygen SpeciessulforaphaneSulfoxidesApotosisBreast cancerERK/MAPK/JNK/p38QuercetinSulforaphane

Identifiers

PMID39760839

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.